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less morning stiffness (p = 0.009), and significantly higher 
scores in seven out of eight SF-36 dimensions compared 
with patients who did not. In multivariable models that 
included all PROs, remission was associated with SF-36 
dimensions higher vitality (odds ratio 2.01; 95% confidence 
interval 1.19–3.39) and better emotional role functioning 
(odds ratio 1.64; 95% confidence interval 1.01–2.68). PGA, 
pain VAS, HAQ, and other SF-36 dimensions were not 
associated with remission. We conclude that self-reported 
vitality and better emotional role functioning are among 
the most important PROs for the prediction of remission in 
ERA.
Keywords Rheumatoid arthritis · Clinical trial · Health-
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Abstract Identifying prognostic factors for remission in 
early rheumatoid arthritis (ERA) patients is of key clinical 
importance. We studied patient-reported outcomes (PROs) 
as predictors of remission in a clinical trial. We randomized 
99 untreated ERA patients to receive remission-targeted 
treatment with three disease-modifying antirheumatic 
drugs and prednisolone for 24 months, and infliximab or 
placebo for the initial 6 months. At baseline, we measured 
following PROs: eight Short Form 36 questionnaire (SF-
36) dimensions, patient’s global assessment [PGA, visual 
analogue scale (VAS)], Health Assessment Questionnaire 
(HAQ), and pain VAS. We used multivariable-adjusted 
regression models to identify PROs that independently 
predicted modified American College of Rheumatology 
remission at 2 years. Follow-up data at 2 years were avail-
able for 93 patients (92%), and 58 patients (62%) were in 
remission. At baseline, patients who achieved remission 
had higher radiological score (p = 0.04), lower tender joint 
count (p = 0.001), lower PGA (p = 0.005) and physician’s 
global assessment (p = 0.019), lower HAQ (p = 0.016), 
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Introduction
At the time of rheumatoid arthritis (RA) diagnosis, it 
is challenging to predict whether a patient will respond 
well to therapy. Multiple factors, including lower disease 
activity, shorter duration of symptoms, and lower Health 
Assessment Questionnaire (HAQ) score, have been recog-
nized as predictors of remission [1].
Numerous studies have also demonstrated that patient-
reported outcomes (PROs) of the American College of 
Rheumatology (ACR) core data set at baseline predict 
long-term outcomes in early RA patients [2, 3]. In RA, also 
individual’s psychological characteristics, like coping strat-
egies and differences in illness perception, may contribute 
to health outcomes [4]. Therefore, quality-of-life instru-
ments including psychological dimensions, like the 36-item 
Short Form Health Survey (SF-36), might be useful in out-
come prediction [5]. To our knowledge, only one previous 
study has examined the role of SF-36 dimensions in pre-
dicting outcomes in an early RA cohort [6].
In the current study, we assessed in a clinical trial setting 
whether 11 PROs measured at baseline (three ACR core 
data set PROs and eight SF-36 dimensions) could predict 
remission independently of other relevant clinical variables 
in intensively treated early RA patients.
Methods
Patients, study flow, and definition of remission
The NEO-RACo (New Finnish Rheumatoid Arthritis 
Combination treatment strategy) trial was an investigator-
initiated, randomized, controlled, double-blind, multicenter 
trial, which enrolled 99 patients with early, active, and dis-
ease-modifying antirheumatic drug-naive RA fulfilling the 
ACR 1987 classification criteria [7]. All included patients 
were of working age (18–60 years). They were assessed 
clinically at weeks 0, 4, 6, 10, 14, 18, 22, 26, at months 8, 
10, 12, and thereafter every 3 months.
Physician’s assessment included tender and swollen joint 
counts, and an assessment of disease activity on a visual 
analogue scale (VAS) of 100 mm. In addition, blood sam-
ples for C-reactive protein, erythrocyte sedimentation rate, 
and rheumatoid factor were drawn. Intensive triple therapy 
consisting of methotrexate (10  mg/week), sulfasalazine 
(1  g/day), hydroxychloroquine (35  mg/kg/wk), and low-
dose oral prednisolone (7.5  mg/day) was initiated in all 
patients. If tolerated, methotrexate and sulfasalazine were 
titrated up to maximum doses of 25 mg/week and 2 g/day. 
Swollen joints were treated with intra-articular glucocorti-
coid injections. In addition, the patients were randomized 
to receive infliximab or placebo infusions at weeks 4, 6, 
10, 18, and 26. If remission was not achieved, or medica-
tion was not tolerated, the treatment with traditional dis-
ease-modifying antirheumatic drugs (DMARDs) had to 
be changed as instructed in the study protocol. Further, in 
treatment failure, defined as less than ACR50 improvement 
at two consecutive visits after week 26 [8], open label use 
of biologic DMARDs as rescue therapy was accepted.
Throughout the study, the treatment was targeted to a 
modified ACR remission, defined as no swollen (66 joint 
count) or tender joints (68 joint count) and presence of 5 
out of the 6 following criteria: morning stiffness <15 min, 
no fatigue, no joint pain, no tender joints, no swell-
ing in joints or tendons, and erythrocyte sedimentation 
rate <30 mm/h in women and <20 mm/h in men. Further, 
disease activity was assessed also using the 28-joint Dis-
ease Activity Score (DAS28) [9]. Patient selection criteria 
of the NEO-RACo trial, as well as the treatment protocol 
and 2-year outcomes, have been described in detail previ-
ously [10].
Patient-reported outcomes
The association between following PROs at baseline and 
modified ACR remission at 24 months was assessed: the 
eight dimensions of the SF-36: vitality, physical function-
ing, bodily pain, general health perceptions, physical role 
functioning, emotional role functioning, social role func-
tioning, and mental health, and the three PROs from the 
ACR core data set: patient’s global assessment of disease 
activity (PGA) on VAS of 100 mm, patient’s assessment of 
pain on VAS of 100 mm, and patient’s assessment of physi-
cal function with HAQ [2, 5]. The following wording of the 
PGA was used: “How would you estimate your rheumatoid 
arthritis disease activity today?”.
Statistical analysis
We made comparisons between groups using t test, 
Mann–Whitney test, or Chi-square test. In the case of vio-
lation of the assumptions (e.g. non-normality), a bootstrap-
type test was used. We estimated odds ratios for remission 
at 24 months for 1-SD increases in PROs using general-
ized maximum entropy estimation methodology for dis-
crete choice models. This method avoids strong parametric 
assumptions, works well with a limited sample size, and 
performs well when the covariates, such as SF-36 dimen-
sions, are highly correlated. The models were adjusted for 
the basic demographic factors (age, sex, and randomization 
group) and poor prognostic factors—rheumatoid factor, 
joint damage (modified Sharp/van der Heijde score), and 
objective measures of disease activity (swollen and tender 
joint counts, erythrocyte sedimentation rate). The normal-
ity of variables was evaluated with the Shapiro–Wilk W 
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test. The data are presented as means with standard devia-
tions or as counts with percentages. STATA 13.1, Stata-
Corp LP (College Station, TX, USA), statistical package 
was used for the analyses.
Results
Follow-up data at 24 months were available for 93 (92%) 
of the 99 patients included in the study. The baseline char-
acteristics of patients who reached and did not reach remis-
sion at 24 months are shown in Table 1. Fifty-eight patients 
(62%) were in remission at 24 months. At baseline, patients 
who achieved remission had lower tender joint count 
(p = 0.001), lower patient’s (p = 0.005) and physician’s 
global assessment (p = 0.019), lower HAQ (p = 0.016), less 
early morning stiffness (p = 0.009), and higher Sharp/van 
der Heijde score (p = 0.04) than patients who did not reach 
remission. The association between remission and SF-36 
dimensions was analysed separately for each dimension. 
All dimensions except mental health (p = 0.12) were associ-
ated with remission at 24 months (Table 2).
Table 1  Baseline 
characteristics of the patients by 
remission status at 24 months
Radiographs were assessed according to the modified Sharp/van der Heijde method
BMI body mass index, IQR interquartile range, DAS28 28-joint Disease Activity Score, ESR erythrocyte 
sedimentation rate, CRP C-reactive protein, PGA patient’s global assessment, VAS visual analogue scale, 
HAQ Health Assessment Questionnaire, PhGA physician’s global assessment
Patient characteristics Remission at 24 months
No (n = 35) Yes (n = 58) p value
Clinical and demographic characteristics at baseline
 Female, n (%) 24 (69) 39 (67) 0.89
 Age (years), mean (SD) 45 (10) 47 (11) 0.61
 BMI (kg/m2), mean (SD) 26.3 (5.0) 25.8 (3.7) 0.59
 Rheumatoid factor present, n (%) 26 (74) 43 (74) 0.99
 Duration of symptoms (months), median (IQR) 4 (2, 4) 4 (2, 7) 0.35
 Randomized to infliximab, n (%) 14 (40) 33 (57) 0.11
Measures of disease activity at baseline
 DAS28, mean (SD) 5.7 (1.3) 5.5 (1.1) 0.31
 ESR (mm/h), mean (SD) 33 (24) 33 (21) 0.92
 CRP (mg/l), mean (SD) 33 (45) 29 (33) 0.56
 Swollen joints (66 joints), mean (SD) 16 (7) 15 (6) 0.41
 Tender joints (68 joints), mean (SD) 25 (12) 17 (9) 0.001
 PGA VAS (mm), mean (SD) 58 (27) 44 (23) 0.005
 Pain VAS (mm), mean (SD) 59 (28) 50 (25) 0.13
 HAQ, mean (SD) 1.2 (0.6) 0.8 (0.6) 0.02
 PhGA VAS (mm), mean (SD) 58 (20) 48 (19) 0.02
 Morning stiffness (min), median (IQR) 120 (100, 240) 90 (60, 180) 0.009
Radiography
 Erosion score, mean (SD) 0.6 (1.2) 2.6 (6.5) 0.02
 Narrowing score, mean (SD) 0.2 (0.6) 0.4 (1.4) 0.51
 Total score, mean (SD) 0.8 (1.6) 2.9 (7.6) 0.04
Table 2  Baseline 36-item Short Form Health Survey (SF-36) dimen-
sions (scale 0–100) by remission status at 24 months
Numbers are reported as mean (SD)
P values are unadjusted
SF-36 dimension Remission at 24 months p value
No Yes
Physical functioning 40 (21) 56 (27) 0.005
Physical role 9 (20) 27 (38) 0.01
Bodily pain 28 (17) 39 (18) 0.003
General health 46 (17) 57 (17) 0.003
Vitality 36 (22) 52 (23) 0.002
Social functioning 59 (28) 75 (24) 0.004
Emotional role 38 (45) 63 (44) 0.01
Mental health 68 (18) 74 (17) 0.12
Summary components
 Physical component 28 (7) 34 (10) 0.003
 Mental component 46 (11) 51 (12) 0.02
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Odds ratios (OR) and 95% confidence intervals (95% 
CI) for remission at 24 months for 1-SD increase in SF-36 
dimensions and ACR core data set PROs are shown in 
Fig.  1. When core data set PROs and SF-36 dimensions 
were simultaneously included in the multivariate logistic 
model, only two SF-36 dimensions, vitality (OR 2.01; 95% 
CI 1.19–3.39) and emotional role functioning (OR 1.64; 
95% CI 1.01–2.68), were associated with increased odds of 
remission.
Discussion
We investigated whether 11 PROs (three ACR core data 
set PROs and eight SF-36 dimensions) could be used as 
predictors of remission in early RA in the era of intensive, 
remission-targeted treatment. In univariable analyses, PGA, 
HAQ, and nearly all dimensions of SF-36 predicted remis-
sion at 24 months. However, when all PROs were simul-
taneously included in the regression models with other 
clinically relevant covariates, only two SF-36 dimensions, 
vitality and emotional role functioning, were associated 
with future remission.
We found only one longitudinal study focused on pre-
dicting remission in early RA using SF-36 dimensions [6]. 
In the study by da Mota et  al., none of the SF-36 dimen-
sions predicted DAS28 remission (DAS28 < 2.6) in a clini-
cal care setting with 40 RA patients. However, only 23% 
of the patients achieved remission in the study. Therefore, 
this study could be underpowered to examine SF-36 dimen-
sions as predictors of outcome. Furthermore, the study was 
an observational cohort study and not a clinical trial, which 
increases the risk of bias. For these reasons, it is difficult to 
compare these results directly with ours.
In our study, none of the ACR core data set PROs (HAQ, 
PGA, and pain VAS) predicted remission at 24 months 
after adjustment for SF-36 dimensions and other clinical 
covariates. HAQ has been previously considered to be one 
of the most important predictors of outcomes in RA [11, 
12]. However, baseline HAQ has not been a potent predic-
tor of clinical remission in early RA in the era of modern 
remission-targeted treatment, a finding confirmed by the 
present study [6, 13]. Another core data set component, 
PGA, has been endorsed as a reliable measure of disease 
activity although it has also been criticized because non-
inflammatory factors, such as pain, seem to contribute to 
the level of PGA [14]. Even though important in clinical 
care, according to our findings, PGA does not seem to be 
useful predictor of future remission.
We found that a 1-SD increase in baseline vitality was 
associated with twofold greater odds of being in remis-
sion at 24 months. Vitality can be defined as the presence 
of energy, well-being, and the absence of fatigue. So far, 
only a few studies have reported about the benefits of vital-
ity to physical health. In these studies, higher vitality has 
been a protective factor against coronary heart disease 
and stroke [15, 16]. In RA studies, the vitality subscale of 
SF-36 has been previously used as a validated measure of 
RA fatigue, defined as low vitality [17]. However, the con-
nection between low vitality (fatigue) and disease activity 
is still being debated as recent reports have demonstrated 
that fatigue may be mediated mainly through factors like 
pain, disability, and poor mental health [18].
Our study was the first to demonstrate that emotional 
role limitations predict remission. Better emotional role 
functioning and higher vitality may reflect patients’ 
healthier psychological functioning. This may, in turn, 
improve patients’ ability to cope with RA and RA treat-
ments resulting in better outcomes. Other previous stud-
ies have also shown that psychosocial interventions, like 
cognitive behavioural therapy, relieve RA symptoms 
effectively [19, 20]. Identifying patients suffering from 
psychological problems could therefore be of key impor-
tance when assessing a patient with newly diagnosed 
Fig. 1  Odds ratios (OR) and 
95% confidence intervals for 
remission at 24 months for 1 
standard deviation (SD) change 
in baseline ACR core data set 
PROs and SF-36 dimensions. 
All variables were simultane-
ously entered into the model. 
ORs are adjusted for age, 
sex, rheumatoid factor status, 
randomization group, baseline 
modified Sharp/van der Heijde 
score, baseline swollen and 
tender joint counts, and baseline 
erythrocyte sedimentation rate
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RA as these individuals might benefit from psychosocial 
interventions. Furthermore, it is possible that by meas-
uring vitality and role-emotional functioning, we can 
grasp aspects of disease activity not detected by simple 
VAS-based PROs. If future studies confirm the accuracy 
of vitality and emotional role functioning in predicting 
remission, questions concerning these SF-36 dimensions 
could be collected during clinic visits.
The results of our study must be interpreted within 
the context of their limitations. First, because our study 
population consisted of intensively treated and followed 
working age patients with early RA, these results may not 
be generalizable to other populations and settings. Sec-
ond, a larger study sample could have resulted in more 
statistically significant associations although this does 
not reduce the significance of vitality and emotional 
role functioning as predictors of remission. Third, SF-36 
vitality scale was the only measure of vitality/fatigue 
used in our study. Because our trial was initiated in 2003, 
measurement of fatigue in RA clinical trials was not yet 
widely recommended and therefore other, possibly more 
comprehensive, fatigue questionnaires were not used. 
Finally, the prognostic factors of RA are often highly cor-
related which complicates statistical analysis. However, 
we tried to minimize the effects of multi-collinearity 
with the use of generalized maximum entropy estimation 
methodology.
Our results show that, of the assessed PROs, only vital-
ity and emotional role functioning are associated with 
higher remission rates in early RA. These self-reported 
measures may reflect patients’ certain personality traits 
or more positive attitude to life. Further, our results also 
underline the importance of detecting patients’ possible 
psychological problems and reacting to them. Further 
studies are needed to elucidate the role and feasibility of 
these PROs as predictors of remission.
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